Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 6/20 | 0.67 |
| ▸ | PDE7B | Q9NP56 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.47 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.47 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6743647 | 0.89 | PDE7A (0.73) | PDE7APDE7BMAPTTXNRD1TXNRD3 | |
| SCHEMBL15307419 | 0.88 | PDE7A (0.64) | PDE7APDE7BMAPTALDH1A1MEN1 | |
| SCHEMBL1567751 | 0.76 | PDE7A (0.56) | PDE7APDE7BMAPTALDH1A1MEN1 | |
| SCHEMBL5980751 | 0.76 | PDE7A (0.56) | PDE7APDE7BMAPTTXNRD1TXNRD3 | |
| SCHEMBL19048971 | 0.76 | PDE7A (0.71) | PDE7APDE7BMAPTTXNRD1TXNRD3 | |
| SCHEMBL2963606 | 0.75 | MAPT (0.55) | PDE7APDE7BMAPTTXNRD1TXNRD3 | |
| SCHEMBL3874156 | 0.75 | PDE7A (0.58) | PDE7AMAPTTXNRD1TXNRD3TXNRD2 | |
| SCHEMBL24155822 | 0.74 | MAPT (0.54) | PDE7AMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL810705 | 0.74 | PDE7A (0.65) | PDE7APDE7BMAPTTXNRD1TXNRD3 | |
| SCHEMBL591089 | 0.73 | MAOA (0.44) | PDE7AMAPTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040029865-A1 | Sleep disorders; eating disorders; schizophrenia disorders; anxiolytic agents | PHARMACIA & UPJOHN COMPANY | 2004-02-12 | — | — | US | disclosed |
| US-20040014966-A1 | Bis-arylsulfones | JACOBSEN ERIC JON (US) | 2004-01-22 | — | — | US | disclosed |
| US-20030225065-A1 | Bis-arylsulfones | JACOBSEN ERIC JON (US) | 2003-12-04 | — | — | US | disclosed |
| WO-2003099797-A1 | SALTS OF BIS-ARYLSULFONES FOR THE TREATMENT OF CNS DISORDERS | PHARMACIA & UPJOHN COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| US-20030207866-A1 | Drugs useful for the treatment of diseases or disorders of the central nervous system. | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | disclosed |
| US-6586592-B2 | Labled isotopes of phenyl 4-(1,4-diazepin-1-yl)-2-amino phenyl sulfone derivatives used in nuclear magnetic resonance imaging and positron emission tomography | PHARMACIA & UPJOHN COMPANY | 2003-07-01 | — | — | US | disclosed |
| US-6579870-B2 | 5-(1,4-diazepan-1-yl)-2-((3 -fluorophenyl)sulfonyl)phenylamine for example; treatment of diseases or disorders of the central nervous system; modulation of serotonin (5-HT) activity | PHARMACIA & UPJOHN COMPANY | 2003-06-17 | — | — | US | disclosed |
| EP-1294701-A2 | BIS-ARYLSULFONES | PHARMACIA & UPJOHN COMPANY (US) | 2003-03-26 | — | — | EP | disclosed |
| US-20020115660-A1 | Bis -arylsulfones | PHARMACIA & UPJOHN COMPANY | 2002-08-22 | — | — | US | disclosed |
| US-20020037892-A1 | Bis-arylsulfones | PHARMACIA & UPJOHN COMPANY | 2002-03-28 | — | — | US | disclosed |
| WO-2001098279-A2 | BIS-ARYLSULFONES | PHARMACIA & UPJOHN COMPANY (US) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207866-A1 | Drugs useful for the treatment of diseases or disorders of the central nervous system. | PMP22, NLN, INA | PDE7A 818/4885PDE7B 933/4885MAPT 204/4885 |
| US-20020037892-A1 | Bis-arylsulfones | PMP22, ARSA, CLN6 | PDE7A 1308/4885PDE7B 1262/4885MAPT 285/4885 |
| US-20040029865-A1 | Sleep disorders; eating disorders; schizophrenia disorders; anxiolytic agents | HCRTR2, HCRTR1, CNR1 | PDE7A 1306/4885PDE7B 580/4885MAPT 3221/4885 |
| US-20020115660-A1 | Bis -arylsulfones | PMP22, ARSA, CLN6 | PDE7A 1308/4885PDE7B 1262/4885MAPT 285/4885 |
| US-20030225065-A1 | Bis-arylsulfones | PMP22, ARSA, CLN6 | PDE7A 1308/4885PDE7B 1262/4885MAPT 285/4885 |
| US-20040014966-A1 | Bis-arylsulfones | NPSR1, ARSA, SLC18A2 | PDE7A 704/4885PDE7B 1299/4885MAPT 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.